within Pharmacolibrary.Drugs.ATC.L;

model L01FX03
  extends Pharmacokinetic.Models.PK_2C(
    weight         = 70,
    F              = 1,
    Cl             = 4.166666666666667e-08,
    adminDuration  = 600,
    adminMass      = 10 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 5e-05,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,            
    Vdp             = 4e-05,
    k12             = 0.0017,
    k21             = 0.0017
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>L01FX03</td></tr><td>route:</td><td>intraperitoneal</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Catumaxomab is a trifunctional monoclonal antibody used in the treatment of malignant ascites in patients with EpCAM-positive carcinomas where standard therapy is not available or no longer feasible. It acts by binding to EpCAM on tumor cells, CD3 on T-cells, and Fcγ receptors on accessory cells to induce tumor cell lysis. It was granted orphan drug status and previously approved in the EU but marketing authorization was withdrawn in 2017; it is not currently approved for routine clinical use.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimation in adult cancer patients after intraperitoneal (i.p.) administration, as data from original studies is scarce and no human PK model with explicit compartmental parameters is published.</p><h4>References</h4><ol><li><p>Ruf, P, et al., &amp; Lindhofer, H (2010). Pharmacokinetics, immunogenicity and bioactivity of the therapeutic antibody catumaxomab intraperitoneally administered to cancer patients. <i>British journal of clinical pharmacology</i> 69(6) 617–625. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.2010.03635.x\">10.1111/j.1365-2125.2010.03635.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20565453/\">https://pubmed.ncbi.nlm.nih.gov/20565453</a></p></li><li><p>Sebastian, M, et al., &amp; Schmittel, A (2009). Catumaxomab: a bispecific trifunctional antibody. <i>Drugs of today (Barcelona, Spain : 1998)</i> 45(8) 589–597. PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19927225/\">https://pubmed.ncbi.nlm.nih.gov/19927225</a></p></li><li><p>Bokemeyer, C (2010). Catumaxomab--trifunctional anti-EpCAM antibody used to treat malignant ascites. <i>Expert opinion on biological therapy</i> 10(8) 1259–1269. DOI:<a href=\"https://doi.org/10.1517/14712598.2010.504706\">10.1517/14712598.2010.504706</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/20624115/\">https://pubmed.ncbi.nlm.nih.gov/20624115</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end L01FX03;
